Communication and Cooperation | Wu Yong, Director of Fujian Union Hospital and Zheng Lemin, Professor of Peking University visited Shenzhen Cell Valley
Recently, Dr. Wu Yong, Director of the Medical Department of the Union Hospital Affiliated to Fujian Medical University, Deputy Director of the Cardiovascular Research Institute of Peking University, distinguished Professor of Peking University Liberal Arts, and Professor Zheng Lemin, a leading scientific and technological innovation talent of the national "Ten thousand People Plan", visited Shenzhen Cell Valley. Our chairman Shi Yuanyuan, chief scientist Wang Jianxun, deputy general manager Tang Xiaomeng, chief medical consultant David Jin, Chairman assistant Wei Zheng and other warm reception.
At the symposium, Professor Shi Yuanyuan focused on the core technical advantages of retrovirus vectors in Shenzhen Cell Valley, recent scientific research achievements, and clinical application cases. Professor Shi Yuanyuan said that Shenzhen Cell Valley has now carried out substantive and comprehensive cooperation with a number of medical institutions, and has so far successfully prepared GMP-level targeting BCMA, CD19, CD19/CD22, CD7, CD38 and other CAR T cell products based on retroviral vectors. Both have shown good safety and efficacy in clinical studies, benefiting more and more patients. Director Wu Yong highly recognized Shenzhen Cell Valley's production and development capabilities as well as the quality management traceability monitoring system in the production of clinical-grade CAR T cell products. At the same time, it is pointed out that although there are monoclonal antibodies and CD19/CD3 bisspecific antibody products for CD19 targets on the market, but its short half-life, serious patients may even need lifelong medication, and CAR-T, CAR-NK and other cell therapies will become a revolutionary means of cancer and other diseases.
Zheng Lemin, professor of Peking University, said that the follow-up of the three parties in the cell therapy of cardiovascular system, nervous system and other related diseases can be from basic scientific research as the starting point of cooperation, seamless connection to clinical transformation; Wu Yong, director of Union Hospital Affiliated to Fujian Medical University, said that he will cooperate closely with Shenzhen Cell Valley, make full use of the strong research and development strength of Shenzhen Cell Valley and GMP industrial production strength as well as the clinical advantages of Fujian Union Hospital, and jointly promote the clinical application of cutting-edge technologies such as cell and gene therapy.
The parties conducted in-depth discussions on possible future cooperation models, through the construction of an open and shared cooperation platform, integration of superior resources of all parties, to achieve win-win results in the two aspects of scientific research results and clinical transformation, and jointly promote the innovative development and application of cell therapy technology.
